Improving patient outcomes: Mepolizumab’s impact in IL-5-mediated diseases
The Interleukin-5 (IL-5)-mediated pathogenic role of eosinophils in airway disorders including severe eosinophilic asthma (SEA), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), and rare hyper-eosinophilic syndrome (HES) is well established. Me...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-05-01
|
| Series: | Lung India |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/lungindia.lungindia_442_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850147862579511296 |
|---|---|
| author | Dipti Gothi Raghupathi Narasimhan Randeep Guleria Manu Chopra Aanchal Gvalani Rashmi Hegde |
| author_facet | Dipti Gothi Raghupathi Narasimhan Randeep Guleria Manu Chopra Aanchal Gvalani Rashmi Hegde |
| author_sort | Dipti Gothi |
| collection | DOAJ |
| description | The Interleukin-5 (IL-5)-mediated pathogenic role of eosinophils in airway disorders including severe eosinophilic asthma (SEA), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), and rare hyper-eosinophilic syndrome (HES) is well established. Mepolizumab, an IL-5-targeting humanised antibody, is approved as an add-on maintenance therapy for SEA, EGPA, CRSwNP, and HES. Here, we review the safety and efficacy findings of mepolizumab in clinical trials and real-world evidence studies in patients with SEA, CRSwNP, EGPA, and HES. We specifically explore the data on mepolizumab that support early initiation of IL-5-targeted therapy to maximise its corticosteroid-sparing effect. This review consolidates the clinical data on mepolizumab, highlights other promising IL-5-targeting agents, and supports the IL-5 pathway as the key therapeutic target across eosinophilic indications. |
| format | Article |
| id | doaj-art-f83d88d4e83f45faa383ea63853e2058 |
| institution | OA Journals |
| issn | 0970-2113 0974-598X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Lung India |
| spelling | doaj-art-f83d88d4e83f45faa383ea63853e20582025-08-20T02:27:25ZengWolters Kluwer Medknow PublicationsLung India0970-21130974-598X2025-05-0142323124410.4103/lungindia.lungindia_442_24Improving patient outcomes: Mepolizumab’s impact in IL-5-mediated diseasesDipti GothiRaghupathi NarasimhanRandeep GuleriaManu ChopraAanchal GvalaniRashmi HegdeThe Interleukin-5 (IL-5)-mediated pathogenic role of eosinophils in airway disorders including severe eosinophilic asthma (SEA), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), and rare hyper-eosinophilic syndrome (HES) is well established. Mepolizumab, an IL-5-targeting humanised antibody, is approved as an add-on maintenance therapy for SEA, EGPA, CRSwNP, and HES. Here, we review the safety and efficacy findings of mepolizumab in clinical trials and real-world evidence studies in patients with SEA, CRSwNP, EGPA, and HES. We specifically explore the data on mepolizumab that support early initiation of IL-5-targeted therapy to maximise its corticosteroid-sparing effect. This review consolidates the clinical data on mepolizumab, highlights other promising IL-5-targeting agents, and supports the IL-5 pathway as the key therapeutic target across eosinophilic indications.https://journals.lww.com/10.4103/lungindia.lungindia_442_24crswnpegpaeosinophilic asthmahyper-eosinophilic syndrome hyper-eosinophiliail-5mepolizumabnucala |
| spellingShingle | Dipti Gothi Raghupathi Narasimhan Randeep Guleria Manu Chopra Aanchal Gvalani Rashmi Hegde Improving patient outcomes: Mepolizumab’s impact in IL-5-mediated diseases Lung India crswnp egpa eosinophilic asthma hyper-eosinophilic syndrome hyper-eosinophilia il-5 mepolizumab nucala |
| title | Improving patient outcomes: Mepolizumab’s impact in IL-5-mediated diseases |
| title_full | Improving patient outcomes: Mepolizumab’s impact in IL-5-mediated diseases |
| title_fullStr | Improving patient outcomes: Mepolizumab’s impact in IL-5-mediated diseases |
| title_full_unstemmed | Improving patient outcomes: Mepolizumab’s impact in IL-5-mediated diseases |
| title_short | Improving patient outcomes: Mepolizumab’s impact in IL-5-mediated diseases |
| title_sort | improving patient outcomes mepolizumab s impact in il 5 mediated diseases |
| topic | crswnp egpa eosinophilic asthma hyper-eosinophilic syndrome hyper-eosinophilia il-5 mepolizumab nucala |
| url | https://journals.lww.com/10.4103/lungindia.lungindia_442_24 |
| work_keys_str_mv | AT diptigothi improvingpatientoutcomesmepolizumabsimpactinil5mediateddiseases AT raghupathinarasimhan improvingpatientoutcomesmepolizumabsimpactinil5mediateddiseases AT randeepguleria improvingpatientoutcomesmepolizumabsimpactinil5mediateddiseases AT manuchopra improvingpatientoutcomesmepolizumabsimpactinil5mediateddiseases AT aanchalgvalani improvingpatientoutcomesmepolizumabsimpactinil5mediateddiseases AT rashmihegde improvingpatientoutcomesmepolizumabsimpactinil5mediateddiseases |